Lv2
108 积分 2024-07-24 加入
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer
16小时前
已完结
The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma With Reversed Polarity of the Breast
8天前
已完结
MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple‐negative breast cancers
9天前
已完结
Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers
1个月前
已完结
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
2个月前
已完结
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
5个月前
已完结
Recent advances in surface plasmon resonance for the detection of ovarian cancer biomarkers: a thorough review
6个月前
已完结
An overview of the research progress of BRCA gene mutations in breast cancer
7个月前
已完结
[Guideline for HER2 detection in breast cancer, the 2019 version]
7个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
7个月前
已完结
皖公网安备34019202002308
